Notably, the detection of CTCs, particularly Fas/FasL co-expressing CTCs, emerged as an adverse prognostic factor, while in contrast, Fas/FasL expression on PBMCs was associated with favorable outcomes of patients with metastatic BC. The gene discussed is FAS; the disease is breast cancer.